Organic electroluminescent materials and devices
US-2015372243-A1 · Dec 24, 2015 · US
Compositions and methods for modulating the activity of Epstein-Barr nuclear antigen 1
US9309212B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9309212-B2 |
| Application number | US-201214119541-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 22, 2012 |
| Priority date | May 24, 2011 |
| Publication date | Apr 12, 2016 |
| Grant date | Apr 12, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention embraces compounds that modulate the activity of Epstein-Barr Nuclear Antigen 1 (BBNA1) protein and use thereof in methods for treating latent Epstein-Barr virus infection. R7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group. A pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable carrier is also provide as are methods for modulating the activity of Epstein-Barr Nuclear Antigen 1 (EBNA1) protein and treating a latent EpsteinBarr virus infection with a composition of the present invention.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for inhibiting the activity of Epstein-Barr Nuclear Antigen 1 (EBNA1) protein comprising contacting an EBNA1 protein with an effective amount of a compound of Formula III: wherein R 7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group, so that the activity of the EBNA1 protein is inhibited. 2. A met…
Assignees
Inventors
Classifications
- C07D307/79Primary
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
- C07D417/12Primary
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9309212B2 cover?
- The present invention embraces compounds that modulate the activity of Epstein-Barr Nuclear Antigen 1 (BBNA1) protein and use thereof in methods for treating latent Epstein-Barr virus infection. R7 is a substituted or unsubstituted phenyl, pyridyl, or pyrimidinyl group. A pharmaceutical composition comprising a compound of the invention in admixture with a pharmaceutically acceptable carrier is…
- Who is the assignee on this patent?
- Lieberman Paul M, Messick Troy, Wistar Inst
- What technology area does this patent fall under?
- Primary CPC classification C07D307/79. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).